Why Shares of Becton, Dickinson Rose Monday
Shares of Becton, Dickinson (NYSE: BDX) were up by more than 6% as of 12:15 p.m. ET Monday, after having climbed by as much as 8.5% shortly after 10 a.m. The medical equipment company announced Friday after the markets closed that the Food and Drug Administration (FDA) had given 510(k) clearance to its new BD Alaris Infusion System with enhanced cybersecurity. The healthcare stock is up more than 10% so far this year.
The new BD Alaris Infusion System is a modular system that includes updated hardware features for large volume pumps, syringe pumps, patient-controlled analgesia (pain-relieving) pumps, along with new software for respiratory monitoring, auto identification, dose error reduction, and electric medical records (EMR) interoperability.
The FDA's decision was a big one, as the old version of Alaris had several recalls. This clearance will allow Becton, Dickinson to begin distributing the system again and remediate or replace older versions of the device that are still being used.
Source Fool.com
Becton, Dickinson & Co. Aktie
Die Becton, Dickinson & Co. Aktie genießt klare Unterstützung: Mehrere Buy-Einschätzungen, keine Sell-Einschätzungen.
Das Kursziel von 257 € für Becton, Dickinson & Co. weist auf eine Steigerung von über 20% gegenüber dem aktuellen Kurs von 211.0 € hin.
